NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Multiple Technology Appraisal (MTA)

Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (including review of TA35)

Please sign and return via NICE Docs/Appraisals.

I confirm that:

- I agree with the content of the submission provided by NRAS and consequently I will not be submitting a personal statement.

Name: [redacted]

Signed: [redacted]

Date: 1/9/15.